Chen C G, Wang Y P, Li Z H
Zhonghua Nei Ke Za Zhi. 1989 May;28(5):277-80, 314.
It appears that Chinese patients had more bleeding complications during anticoagulative and thrombolytic therapies than western populations. To determine the effect of a moderate dosage of urokinase for Chinese patients with evolving acute myocardial infarction (AMI), we studied 17 patients with AMI. The patients were divided into 2 groups: Urokinase group (UG) and control group (CG). Seven patients in UG, having AMI 5.1 +/- 1.3 hours after the onset received intravenous urokinase 250,000-450,000 units within 30 minutes and then were treated with heparin. Ten patients in CG, having AMI 12.1 +/- 10.1 hours after the onset received conventional therapy as well as heparin. The successful reperfusion of coronary artery was assessed noninvasively using peak CPK level less than 18 hours and elevated ST segment normalization within 24 hours as the criteria.
Successful reperfusion was found in 5 of 7 patients in UG and in only 1 of 10 patients in CG (P less than 0.05). No gastrointestinal and cerebrovascular bleeding or other major bleeding complications were observed in UG, while 1 of 10 patients in CG had gastric bleeding requiring transfusion. The mortality during 2 months of hospitalization was 2/10 (20%) in CG, but no patient in UG died during 2 months of hospital stay. The results of the study suggest that moderate dosage of urokinase could achieve reperfusion in majority of Chinese patients with AMI and may have less bleeding complications. However, randomized and large-group patient studies are needed to confirm the presented results.
中国患者在抗凝和溶栓治疗期间出现的出血并发症似乎比西方人群更多。为了确定中等剂量尿激酶对中国进展期急性心肌梗死(AMI)患者的疗效,我们研究了17例AMI患者。患者分为两组:尿激酶组(UG)和对照组(CG)。UG组的7例患者在发病后5.1±1.3小时接受静脉注射尿激酶250,000 - 450,000单位,30分钟内完成,随后接受肝素治疗。CG组的10例患者在发病后12.1±10.1小时接受常规治疗及肝素治疗。冠状动脉再灌注成功的评估标准为发病后18小时内CPK峰值低于正常水平以及24小时内ST段抬高恢复正常,采用非侵入性方法进行评估。
UG组7例患者中有5例再灌注成功,而CG组10例患者中仅有1例成功(P<0.05)。UG组未观察到胃肠道和脑血管出血或其他严重出血并发症,而CG组10例患者中有1例出现胃出血需要输血治疗。CG组住院2个月期间的死亡率为2/10(20%),但UG组在住院2个月期间无患者死亡。研究结果表明,中等剂量的尿激酶可使大多数中国AMI患者实现再灌注,且可能具有较少的出血并发症。然而,需要进行随机、大样本患者研究以证实上述结果。